VCM
ONCE

Vivaldi Capital Management’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History

Vivaldi Capital Management’s Portfolio ONCE Stock Details ONCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-2,855
Closed -$325K – 252
2019
Q1 		$325K Buy
+2,855
New +$210K 0.09% 172

Other funds holding ONCE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Magnetar Financial
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return
Pentwater Capital Management
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
Farallon Capital Management
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vivaldi Capital Management's ONCE Position: Q2 2019 in Review

Vivaldi Capital Management sold out of Spark Therapeutics, Inc. Common Stock (ONCE) in Q2 2019, closing a stake of 2,855 shares — an estimated $325K sold.

Vivaldi Capital Management first reported a position in ONCE in Q1 2019 and held it in 1 quarter. The position peaked at $325K in Q1 2019. 194 funds tracked by Wall St. Rank hold ONCE as of Q2 2019.

  • Vivaldi Capital Management reported no remaining Spark Therapeutics, Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
  • Vivaldi Capital Management sold 2,855 Spark Therapeutics, Inc. Common Stock shares in Q2 2019, an estimated $325K.
  • Vivaldi Capital Management first reported a position in Spark Therapeutics, Inc. Common Stock in Q1 2019 and held it in 1 quarter.
  • Vivaldi Capital Management's Spark Therapeutics, Inc. Common Stock position peaked at $325K in Q1 2019.
  • 194 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q2 2019.

Based on Vivaldi Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.